|
|
|
| home > white papers > Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models - DrugDev |
|
|
 WHITE PAPERS |
|
DrugDev
|
|
Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models
|
|
For the last 20 years, pharmaceutical companies have turned to a variety
of clinical outsourcing solutions to reduce costs and improve
timelines, enabling them to focus on their core value of research and
development. In today’s tightly competitive market, companies are
constantly striving for ways to further cut costs and reduce study
startup cycle times, while maintaining quality.
One of the key
cost factors in global R&D spending, estimated at around $102
billion per Kalorama market research, is the cost of conducting clinical
trials. CRO’s, which account for about 30% of the total R&D
spending, have risen to the challenge of the clinical, technical and
administrative management of these trials. But some pharmaceutical
companies question how much control to relinquish to vendor partners,
especially in the legal arena, due to potential ramifications.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Syntegon and Vetter win PDA Drug Delivery Innovation Award for Versynta microBatch
Waiblingen/Germany, October 6, 2021. Together with Vetter, an
international pharmaceutical service provider for injectables, Syntegon
(formerly Bosch Packaging Technology) has won the PDA Drug Delivery
Innovation Award. In the "Partnership Innovation" category, the Parental
Drug Association (PDA) honors development projects by pharmaceutical
and machine manufacturers that advance the production of
(bio)pharmaceuticals. The collaboration between Vetter and Syntegon
resulted in Versynta microBatch, a highly flexible and fully automated
production cell with a gloveless isolator, the smallest possible
dimensions and a complete batch-to-batch changeover of less than two
hours.
More info >> |
|
 |
White Papers |
 |
|
Customising the Cold Chain
World Courier
Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >> |
|
|
|
